drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01037 | DB01309 | 1,161 | 1,254 | [
"DDInter1653",
"DDInter933"
] | Selegiline | Insulin glulisine | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1161,
24,
1254
]
],
[
[
1161,
63,
274
],
[
274,
23,
1254
]
],
[
[
1161,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
1161,
1,
280
],
[
280,
... | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib an... |
DB04953 | DB11113 | 495 | 657 | [
"DDInter708",
"DDInter307"
] | Ezogabine | Castor oil | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
495,
24,
657
]
],
[
[
495,
24,
927
],
[
927,
63,
657
]
],
[
[
495,
24,
1491
],
[
1491,
24,
657
]
],
[
[
495,
25,
985
],
[
985,
2... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midos... |
DB01035 | DB01218 | 1,401 | 1,493 | [
"DDInter1524",
"DDInter852"
] | Procainamide | Halofantrine | A derivative of procaine with less CNS action. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1401,
25,
1493
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
1401,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1401,
62,
112
],
[
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Procainamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Procainamide (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Procainamide may cause a minor interaction that can limit clinical effects whe... |
DB01238 | DB01246 | 673 | 820 | [
"DDInter118",
"DDInter45"
] | Aripiprazole | Alimemazine | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
673,
24,
820
]
],
[
[
673,
63,
104
],
[
104,
40,
820
]
],
[
[
673,
63,
401
],
[
401,
24,
820
]
],
[
[
673,
24,
649
],
[
649,
1,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interacti... |
DB00476 | DB08880 | 109 | 1,510 | [
"DDInter608",
"DDInter1771"
] | Duloxetine | Teriflunomide | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
109,
25,
1510
]
],
[
[
109,
24,
741
],
[
741,
63,
1510
]
],
[
[
109,
63,
1061
],
[
1061,
24,
1510
]
],
[
[
109,
24,
752
],
[
752,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
],
[
"Rolapit... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and T... |
DB00703 | DB09564 | 997 | 1,296 | [
"DDInter1167",
"DDInter930"
] | Methazolamide | Insulin degludec | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
997,
24,
1296
]
],
[
[
997,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
997,
64,
1645
],
[
1645,
24,
1296
]
],
[
[
997,
62,
964
],
[
964,
... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Methazolamide may lead to a major life threatening interaction when taken with Metformin and Metformi... |
DB00252 | DB00507 | 362 | 316 | [
"DDInter1460",
"DDInter1299"
] | Phenytoin | Nitazoxanide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses.... | Moderate | 1 | [
[
[
362,
24,
316
]
],
[
[
362,
23,
1479
],
[
1479,
1,
316
]
],
[
[
362,
18,
17148
],
[
17148,
57,
316
]
],
[
[
362,
21,
28779
],
[
28779,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanide"
]
],
[
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
... | Phenytoin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Nitazoxanide (Compound)
Phenytoin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Nitazoxanide (Compound)
Phenytoin (Compound) causes Dr... |
DB11978 | DB11979 | 124 | 1,320 | [
"DDInter822",
"DDInter625"
] | Glasdegib | Elagolix | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
124,
24,
1320
]
],
[
[
124,
63,
271
],
[
271,
23,
1320
]
],
[
[
124,
63,
1297
],
[
1297,
24,
1320
]
],
[
[
124,
64,
1249
],
[
1249,
... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrost... |
DB01010 | DB11363 | 61 | 1,276 | [
"DDInter622",
"DDInter39"
] | Edrophonium | Alectinib | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
61,
24,
1276
]
],
[
[
61,
63,
190
],
[
190,
24,
1276
]
],
[
[
61,
24,
1011
],
[
1011,
24,
1276
]
],
[
[
61,
24,
1476
],
[
1476,
... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Succinylcholine"
],
... | Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Succinylcholine and Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod... |
DB00073 | DB14409 | 1,394 | 1,129 | [
"DDInter1608",
"DDInter867"
] | Rituximab | Human adenovirus e serotype 4 strain cl-68578 antigen | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1394,
24,
1129
]
],
[
[
1394,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1394,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
1394,
63,
1184
],
[
11... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"E... | Rituximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Rituximab may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00491 | DB01285 | 127 | 708 | [
"DDInter1217",
"DDInter445"
] | Miglitol | Corticotropin | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
127,
24,
708
]
],
[
[
127,
24,
659
],
[
659,
62,
708
]
],
[
[
127,
24,
1052
],
[
1052,
23,
708
]
],
[
[
127,
63,
245
],
[
245,
2... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine ... |
DB00059 | DB04835 | 1,560 | 1,655 | [
"DDInter1404",
"DDInter1125"
] | Pegaspargase | Maraviroc | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
1560,
24,
1655
]
],
[
[
1560,
24,
1419
],
[
1419,
24,
1655
]
],
[
[
1560,
24,
1468
],
[
1468,
63,
1655
]
],
[
[
1560,
63,
1648
],
[
16... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatini... |
DB09104 | DB11189 | 286 | 1,333 | [
"DDInter1118",
"DDInter1117"
] | Magnesium hydroxide | Magnesium glycinate | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency. | Moderate | 1 | [
[
[
286,
24,
1333
]
],
[
[
286,
24,
460
],
[
460,
24,
1333
]
],
[
[
286,
63,
1331
],
[
1331,
24,
1333
]
],
[
[
286,
64,
1231
],
[
1231,
... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium glycinate"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium glycinate
Magnesium hydroxide may cause a moderate interaction that could exacerbate d... |
DB00321 | DB00836 | 21 | 543 | [
"DDInter78",
"DDInter1088"
] | Amitriptyline | Loperamide | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
21,
24,
543
]
],
[
[
21,
24,
649
],
[
649,
1,
543
]
],
[
[
21,
24,
262
],
[
262,
24,
543
]
],
[
[
21,
63,
701
],
[
701,
24,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that c... |
DB00002 | DB01101 | 1,284 | 60 | [
"DDInter344",
"DDInter285"
] | Cetuximab | Capecitabine | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
1284,
24,
60
]
],
[
[
1284,
24,
4
],
[
4,
63,
60
]
],
[
[
1284,
24,
1555
],
[
1555,
24,
60
]
],
[
[
1284,
25,
770
],
[
770,
25,
... | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
... | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Cetuximab may cause a moderate interaction that could exacerbate diseases when ta... |
DB00717 | DB09564 | 1,197 | 1,296 | [
"DDInter1312",
"DDInter930"
] | Norethisterone | Insulin degludec | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1197,
24,
1296
]
],
[
[
1197,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1197,
63,
1645
],
[
1645,
24,
1296
]
],
[
[
1197,
1,
1336
],
[
133... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Metfo... |
DB11967 | DB15233 | 710 | 1,650 | [
"DDInter210",
"DDInter142"
] | Binimetinib | Avapritinib | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
710,
25,
1650
]
],
[
[
710,
63,
1478
],
[
1478,
24,
1650
]
],
[
[
710,
24,
1320
],
[
1320,
24,
1650
]
],
[
[
710,
63,
1512
],
[
1512,
... | [
[
[
"Binimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacafto... | Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagoli... |
DB08899 | DB09078 | 129 | 1,228 | [
"DDInter649",
"DDInter1036"
] | Enzalutamide | Lenvatinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
129,
24,
1228
]
],
[
[
129,
62,
112
],
[
112,
23,
1228
]
],
[
[
129,
63,
463
],
[
463,
23,
1228
]
],
[
[
129,
63,
1100
],
[
1100,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and ... |
DB00776 | DB06691 | 1,335 | 849 | [
"DDInter1360",
"DDInter1155"
] | Oxcarbazepine | Mepyramine | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1335,
24,
849
]
],
[
[
1335,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1335,
24,
272
],
[
272,
24,
849
]
],
[
[
1335,
24,
407
],
[
407,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramin... |
DB06788 | DB08868 | 1,616 | 1,011 | [
"DDInter864",
"DDInter737"
] | Histrelin | Fingolimod | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1616,
25,
1011
]
],
[
[
1616,
62,
1247
],
[
1247,
23,
1011
]
],
[
[
1616,
24,
144
],
[
144,
63,
1011
]
],
[
[
1616,
63,
867
],
[
867,
... | [
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Histrelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamet... | Histrelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and ... |
DB00242 | DB00851 | 1,064 | 611 | [
"DDInter392",
"DDInter463"
] | Cladribine | Dacarbazine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Major | 2 | [
[
[
1064,
25,
611
]
],
[
[
1064,
5,
11555
],
[
11555,
44,
611
]
],
[
[
1064,
7,
7669
],
[
7669,
46,
611
]
],
[
[
1064,
25,
141
],
[
141,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacarbazine"
]
],
[
[
"Cladribine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated ... | Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dacarbazine (Compound)
Cladribine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Dacarbazine (Compound)
Cladribine may lead to a major life threatening interaction when taken with Floxuridine... |
DB00884 | DB01082 | 1,008 | 1,448 | [
"DDInter1604",
"DDInter1713"
] | Risedronic acid | Streptomycin | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
1008,
24,
1448
]
],
[
[
1008,
21,
28882
],
[
28882,
60,
1448
]
],
[
[
1008,
24,
361
],
[
361,
24,
1448
]
],
[
[
1008,
63,
1512
],
[
15... | [
[
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Risedronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperatur... | Risedronic acid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Streptomycin (Compound)
Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could e... |
DB00975 | DB01242 | 1,317 | 1,237 | [
"DDInter573",
"DDInter410"
] | Dipyridamole | Clomipramine | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1317,
24,
1237
]
],
[
[
1317,
6,
4973
],
[
4973,
45,
1237
]
],
[
[
1317,
21,
28703
],
[
28703,
60,
1237
]
],
[
[
1317,
64,
1578
],
[
1... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Dipyridamole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Dipyridamole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clomipramine (Compound)
Dipyridamole (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Clomipramine (Compound)
Dipyridamole may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may ... |
DB00539 | DB06402 | 11 | 1,079 | [
"DDInter1837",
"DDInter1756"
] | Toremifene | Telavancin | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Major | 2 | [
[
[
11,
25,
1079
]
],
[
[
11,
24,
968
],
[
968,
40,
1079
]
],
[
[
11,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
11,
23,
112
],
[
112,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telavancin"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oritavancin"
],
[
"Oritavanc... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Oritavancin and Oritavancin (Compound) resembles Telavancin (Compound)
Toremifene (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Toremifene may cause a minor interaction that can li... |
DB00401 | DB06674 | 84 | 908 | [
"DDInter1298",
"DDInter837"
] | Nisoldipine | Golimumab | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
84,
24,
908
]
],
[
[
84,
1,
336
],
[
336,
24,
908
]
],
[
[
84,
40,
1428
],
[
1428,
24,
908
]
],
[
[
84,
62,
1031
],
[
1031,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Nisoldipine",
"{u} (Compound) resembles {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a modera... | Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Nisoldipine (Compound) resembles Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
... |
DB00261 | DB05316 | 702 | 749 | [
"DDInter93",
"DDInter1467"
] | Anagrelide | Pimavanserin | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Major | 2 | [
[
[
702,
25,
749
]
],
[
[
702,
23,
112
],
[
112,
23,
749
]
],
[
[
702,
25,
1264
],
[
1264,
24,
749
]
],
[
[
702,
64,
521
],
[
521,
2... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimavanserin"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Anagrelide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a ... |
DB00586 | DB01174 | 1,512 | 697 | [
"DDInter537",
"DDInter1442"
] | Diclofenac | Phenobarbital | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Minor | 0 | [
[
[
1512,
23,
697
]
],
[
[
1512,
6,
7950
],
[
7950,
45,
697
]
],
[
[
1512,
21,
28860
],
[
28860,
60,
697
]
],
[
[
1512,
63,
1018
],
[
1018... | [
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Diclofenac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Phenobarbital (Compound)
Diclofenac (Compound) causes Mental disability (Side Effect) and Mental disability (Side Effect) is caused by Phenobarbital (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00420 | DB01276 | 508 | 123 | [
"DDInter1532",
"DDInter706"
] | Promazine | Exenatide | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
508,
24,
123
]
],
[
[
508,
1,
820
],
[
820,
24,
123
]
],
[
[
508,
40,
1630
],
[
1630,
24,
123
]
],
[
[
508,
24,
222
],
[
222,
24... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate... | Promazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Promazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Exenatid... |
DB00581 | DB06663 | 355 | 1,154 | [
"DDInter1018",
"DDInter1398"
] | Lactulose | Pasireotide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
355,
24,
1154
]
],
[
[
355,
21,
28810
],
[
28810,
60,
1154
]
],
[
[
355,
40,
1647
],
[
1647,
24,
1154
]
],
[
[
355,
24,
1662
],
[
1662... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Lactulose",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u... | Lactulose (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Pasireotide (Compound)
Lactulose (Compound) resembles Acarbose (Compound) and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Lactulose may cause a mo... |
DB00087 | DB06603 | 599 | 39 | [
"DDInter41",
"DDInter1387"
] | Alemtuzumab | Panobinostat | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Moderate | 1 | [
[
[
599,
24,
39
]
],
[
[
599,
63,
1257
],
[
1257,
24,
39
]
],
[
[
599,
24,
221
],
[
221,
63,
39
]
],
[
[
599,
24,
58
],
[
58,
24,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus ... |
DB08873 | DB09074 | 74 | 1,362 | [
"DDInter221",
"DDInter1327"
] | Boceprevir | Olaparib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Major | 2 | [
[
[
74,
25,
1362
]
],
[
[
74,
63,
896
],
[
896,
24,
1362
]
],
[
[
74,
64,
1478
],
[
1478,
24,
1362
]
],
[
[
74,
24,
1619
],
[
1619,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Boceprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
... | Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Boceprevir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a mode... |
DB00278 | DB06081 | 291 | 1,046 | [
"DDInter117",
"DDInter286"
] | Argatroban | Caplacizumab | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
291,
25,
1046
]
],
[
[
291,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
291,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
291,
24,
1427
],
[
1427,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Argatroban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",
... | Argatroban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenf... |
DB01166 | DB06779 | 477 | 365 | [
"DDInter379",
"DDInter470"
] | Cilostazol | Dalteparin | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
477,
25,
365
]
],
[
[
477,
23,
539
],
[
539,
62,
365
]
],
[
[
477,
63,
305
],
[
305,
24,
365
]
],
[
[
477,
24,
1496
],
[
1496,
6... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli... |
DB08816 | DB09083 | 578 | 880 | [
"DDInter1802",
"DDInter996"
] | Ticagrelor | Ivabradine | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
578,
24,
880
]
],
[
[
578,
24,
1478
],
[
1478,
24,
880
]
],
[
[
578,
24,
159
],
[
159,
63,
880
]
],
[
[
578,
63,
1051
],
[
1051,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00254 | DB00774 | 964 | 1,577 | [
"DDInter598",
"DDInter889"
] | Doxycycline | Hydroflumethiazide | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Minor | 0 | [
[
[
964,
23,
1577
]
],
[
[
964,
23,
359
],
[
359,
40,
1577
]
],
[
[
964,
23,
504
],
[
504,
1,
1577
]
],
[
[
964,
40,
1620
],
[
1620,
... | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]... | Doxycycline may cause a minor interaction that can limit clinical effects when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) ... |
DB00480 | DB00631 | 1,668 | 372 | [
"DDInter1035",
"DDInter405"
] | Lenalidomide | Clofarabine | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1668,
24,
372
]
],
[
[
1668,
64,
1064
],
[
1064,
25,
372
]
],
[
[
1668,
5,
11555
],
[
11555,
44,
372
]
],
[
[
1668,
6,
7720
],
[
7720,... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladr... | Lenalidomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Clofarabine
Lenalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Clofarabine (Compound)
Lenalidom... |
DB00283 | DB01209 | 701 | 1,359 | [
"DDInter395",
"DDInter531"
] | Clemastine | Dezocine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
701,
24,
1359
]
],
[
[
701,
24,
234
],
[
234,
1,
1359
]
],
[
[
701,
24,
717
],
[
717,
24,
1359
]
],
[
[
701,
35,
1594
],
[
1594,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interact... |
DB00358 | DB00373 | 1,010 | 461 | [
"DDInter1140",
"DDInter1809"
] | Mefloquine | Timolol | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
1010,
24,
461
]
],
[
[
1010,
24,
729
],
[
729,
40,
461
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
461
]
],
[
[
1010,
21,
28814
],
[
28814,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Timolol (Compound)
Mefloquine (Compound) causes Affect lability (Side Effect) and Affect labi... |
DB00980 | DB09280 | 969 | 1,604 | [
"DDInter1564",
"DDInter1101"
] | Ramelteon | Lumacaftor | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
969,
24,
1604
]
],
[
[
969,
63,
254
],
[
254,
24,
1604
]
],
[
[
969,
24,
985
],
[
985,
64,
1604
]
],
[
[
969,
24,
868
],
[
868,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimert... |
DB00719 | DB11915 | 1,219 | 1,293 | [
"DDInter149",
"DDInter1909"
] | Azatadine | Valbenazine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
1219,
24,
1293
]
],
[
[
1219,
24,
516
],
[
516,
24,
1293
]
],
[
[
1219,
63,
1242
],
[
1242,
24,
1293
]
],
[
[
1219,
40,
830
],
[
830,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and... |
DB00570 | DB10795 | 147 | 221 | [
"DDInter1936",
"DDInter1486"
] | Vinblastine | Poliovirus type 1 antigen (formaldehyde inactivated) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
147,
24,
221
]
],
[
[
147,
24,
36
],
[
36,
24,
221
]
],
[
[
147,
64,
581
],
[
581,
24,
221
]
],
[
[
147,
63,
599
],
[
599,
24,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Vinblastine may lead to a major life threatening interaction when taken w... |
DB08875 | DB11967 | 1,618 | 710 | [
"DDInter262",
"DDInter210"
] | Cabozantinib | Binimetinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Major | 2 | [
[
[
1618,
25,
710
]
],
[
[
1618,
64,
441
],
[
441,
24,
710
]
],
[
[
1618,
25,
1293
],
[
1293,
24,
710
]
],
[
[
1618,
25,
68
],
[
68,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Binimetinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Delavirdine"
],
[
"Delavirdine",
... | Cabozantinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Cabozantinib may lead to a major life threatening interaction when taken with Valbenazine and Valbenazine may cause a mode... |
DB01118 | DB09036 | 33 | 812 | [
"DDInter76",
"DDInter1668"
] | Amiodarone | Siltuximab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
33,
24,
812
]
],
[
[
33,
24,
792
],
[
792,
24,
812
]
],
[
[
33,
63,
1031
],
[
1031,
24,
812
]
],
[
[
33,
64,
126
],
[
126,
24,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Th... |
DB01009 | DB09135 | 935 | 1,211 | [
"DDInter1009",
"DDInter967"
] | Ketoprofen | Ioxilan | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
935,
25,
1211
]
],
[
[
935,
1,
1523
],
[
1523,
24,
1211
]
],
[
[
935,
24,
712
],
[
712,
25,
1211
]
],
[
[
935,
63,
372
],
[
372,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that c... | Ketoprofen (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction... |
DB00544 | DB14443 | 970 | 987 | [
"DDInter757",
"DDInter1931"
] | Fluorouracil | Vibrio cholerae CVD 103-HgR strain live antigen | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
970,
24,
987
]
],
[
[
970,
63,
141
],
[
141,
24,
987
]
],
[
[
970,
24,
1488
],
[
1488,
24,
987
]
],
[
[
970,
64,
377
],
[
377,
2... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Fluorouracil may cause a moderate interaction that could exacerbate dis... |
DB00544 | DB06372 | 970 | 259 | [
"DDInter757",
"DDInter1594"
] | Fluorouracil | Rilonacept | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
970,
24,
259
]
],
[
[
970,
63,
1461
],
[
1461,
23,
259
]
],
[
[
970,
24,
0
],
[
0,
24,
259
]
],
[
[
970,
40,
132
],
[
132,
24,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Dactinomycin and Dact... |
DB00818 | DB11730 | 898 | 351 | [
"DDInter1538",
"DDInter1588"
] | Propofol | Ribociclib | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
898,
24,
351
]
],
[
[
898,
23,
112
],
[
112,
23,
351
]
],
[
[
898,
63,
355
],
[
355,
24,
351
]
],
[
[
898,
24,
1491
],
[
1491,
2... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose... |
DB00026 | DB01168 | 1,184 | 1,053 | [
"DDInter94",
"DDInter1526"
] | Anakinra | Procarbazine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1184,
24,
1053
]
],
[
[
1184,
24,
126
],
[
126,
23,
1053
]
],
[
[
1184,
24,
496
],
[
496,
63,
1053
]
],
[
[
1184,
24,
1648
],
[
1648,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepat... |
DB01105 | DB11632 | 222 | 580 | [
"DDInter1665",
"DDInter1343"
] | Sibutramine | Opicapone | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
222,
24,
580
]
],
[
[
222,
24,
649
],
[
649,
24,
580
]
],
[
[
222,
63,
401
],
[
401,
24,
580
]
],
[
[
222,
64,
506
],
[
506,
24,... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB01082 | DB01181 | 1,448 | 1,532 | [
"DDInter1713",
"DDInter906"
] | Streptomycin | Ifosfamide | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1448,
24,
1532
]
],
[
[
1448,
21,
28725
],
[
28725,
60,
1532
]
],
[
[
1448,
63,
1132
],
[
1132,
24,
1532
]
],
[
[
1448,
24,
445
],
[
4... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Streptomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effec... | Streptomycin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Ifosfamide (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01229 | DB08860 | 973 | 788 | [
"DDInter1378",
"DDInter1479"
] | Paclitaxel (protein-bound) | Pitavastatin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
973,
24,
788
]
],
[
[
973,
63,
671
],
[
671,
1,
788
]
],
[
[
973,
63,
700
],
[
700,
40,
788
]
],
[
[
973,
6,
17404
],
[
17404,
4... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Paclitaxel may cause a moderate interaction that cou... |
DB00549 | DB11837 | 522 | 1,297 | [
"DDInter1955",
"DDInter1351"
] | Zafirlukast | Osilodrostat | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
522,
24,
1297
]
],
[
[
522,
24,
112
],
[
112,
23,
1297
]
],
[
[
522,
23,
222
],
[
222,
23,
1297
]
],
[
[
522,
23,
907
],
[
907,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and... |
DB00308 | DB11978 | 347 | 124 | [
"DDInter901",
"DDInter822"
] | Ibutilide | Glasdegib | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
347,
25,
124
]
],
[
[
347,
23,
112
],
[
112,
23,
124
]
],
[
[
347,
25,
79
],
[
79,
24,
124
]
],
[
[
347,
24,
688
],
[
688,
24,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Ibutilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Ibutilide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a m... |
DB00222 | DB01267 | 245 | 519 | [
"DDInter825",
"DDInter1381"
] | Glimepiride | Paliperidone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
245,
24,
519
]
],
[
[
245,
24,
1664
],
[
1664,
1,
519
]
],
[
[
245,
21,
28826
],
[
28826,
60,
519
]
],
[
[
245,
40,
959
],
[
959,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Glimepiride (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Paliperidone (Compound)
Glimepiride (Compound) resembles Glipi... |
DB06410 | DB12130 | 1,196 | 1,017 | [
"DDInter595",
"DDInter1094"
] | Doxercalciferol | Lorlatinib | Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney d... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1196,
24,
1017
]
],
[
[
1196,
64,
1041
],
[
1041,
24,
1017
]
],
[
[
1196,
24,
214
],
[
214,
24,
1017
]
],
[
[
1196,
24,
1654
],
[
1654... | [
[
[
"Doxercalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Doxercalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paricalcitol"
],
[
... | Doxercalciferol may lead to a major life threatening interaction when taken with Paricalcitol and Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Doxercalciferol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fosta... |
DB06717 | DB12130 | 875 | 1,017 | [
"DDInter778",
"DDInter1094"
] | Fosaprepitant | Lorlatinib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
875,
24,
1017
]
],
[
[
875,
63,
608
],
[
608,
23,
1017
]
],
[
[
875,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
875,
63,
175
],
[
175,
... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexaro... |
DB00559 | DB01105 | 152 | 222 | [
"DDInter223",
"DDInter1665"
] | Bosentan | Sibutramine | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
152,
24,
222
]
],
[
[
152,
6,
8374
],
[
8374,
45,
222
]
],
[
[
152,
21,
29215
],
[
29215,
60,
222
]
],
[
[
152,
24,
384
],
[
384,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Bosentan (Compound) causes Ecchymosis (Side Effect) and Ecchymosis (Side Effect) is caused by Sibutramine (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelal... |
DB00065 | DB00252 | 581 | 362 | [
"DDInter923",
"DDInter1460"
] | Infliximab | Phenytoin | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Moderate | 1 | [
[
[
581,
24,
362
]
],
[
[
581,
24,
759
],
[
759,
40,
362
]
],
[
[
581,
24,
126
],
[
126,
63,
362
]
],
[
[
581,
25,
1101
],
[
1101,
6... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenytoin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacer... |
DB00574 | DB09030 | 121 | 840 | [
"DDInter717",
"DDInter1945"
] | Fenfluramine | Vorapaxar | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
121,
24,
840
]
],
[
[
121,
64,
529
],
[
529,
24,
840
]
],
[
[
121,
24,
885
],
[
885,
24,
840
]
],
[
[
121,
25,
1039
],
[
1039,
2... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvox... | Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol m... |
DB10316 | DB14762 | 334 | 994 | [
"DDInter1248",
"DDInter1602"
] | Mumps virus strain B level jeryl lynn live antigen | Risankizumab | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Major | 2 | [
[
[
334,
25,
994
]
],
[
[
334,
64,
4
],
[
4,
24,
994
]
],
[
[
334,
25,
270
],
[
270,
24,
994
]
],
[
[
334,
25,
676
],
[
676,
64,
... | [
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Risankizumab"
]
],
[
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when... | Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Mumps virus strain B level jeryl lynn live antigen may ... |
DB00572 | DB00808 | 85 | 1,605 | [
"DDInter136",
"DDInter916"
] | Atropine | Indapamide | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Minor | 0 | [
[
[
85,
23,
1605
]
],
[
[
85,
62,
811
],
[
811,
1,
1605
]
],
[
[
85,
21,
28640
],
[
28640,
60,
1605
]
],
[
[
85,
24,
1511
],
[
1511,
... | [
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metolazone"
],
[
"Met... | Atropine may cause a minor interaction that can limit clinical effects when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Atropine (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Indapamide (Compound)
Atropine may cause a moderate interaction that c... |
DB08816 | DB09098 | 578 | 98 | [
"DDInter1802",
"DDInter1700"
] | Ticagrelor | Somatrem | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
578,
24,
98
]
],
[
[
578,
23,
1459
],
[
1459,
23,
98
]
],
[
[
578,
62,
336
],
[
336,
24,
98
]
],
[
[
578,
63,
1671
],
[
1671,
24... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
],
[
... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine and Nifedipine... |
DB00662 | DB01114 | 717 | 272 | [
"DDInter1873",
"DDInter362"
] | Trimethobenzamide | Chlorpheniramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
717,
24,
272
]
],
[
[
717,
24,
358
],
[
358,
63,
272
]
],
[
[
717,
63,
128
],
[
128,
24,
272
]
],
[
[
717,
21,
28705
],
[
28705,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphena... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01218 | DB09020 | 1,493 | 28 | [
"DDInter852",
"DDInter212"
] | Halofantrine | Bisacodyl | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1493,
24,
28
]
],
[
[
1493,
7,
5998
],
[
5998,
46,
28
]
],
[
[
1493,
18,
3023
],
[
3023,
57,
28
]
],
[
[
1493,
21,
28809
],
[
28809,
... | [
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Halofantrine",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v}... | Halofantrine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Bisacodyl (Compound)
Halofantrine (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Bisacodyl (Compound)
Halofantrine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacody... |
DB00472 | DB01166 | 758 | 477 | [
"DDInter758",
"DDInter379"
] | Fluoxetine | Cilostazol | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
758,
24,
477
]
],
[
[
758,
6,
8374
],
[
8374,
45,
477
]
],
[
[
758,
7,
3727
],
[
3727,
46,
477
]
],
[
[
758,
21,
28919
],
[
28919,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Fluoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Fluoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Fluoxetine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Cilostazol (Compound)
Fluoxetine (Compound) causes Arthritis (Side Effect) and Arthritis (Side Effect) is caused by Cilostazol (Compound)
Fluoxetine... |
DB01045 | DB09330 | 463 | 985 | [
"DDInter1590",
"DDInter1352"
] | Rifampicin | Osimertinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
463,
25,
985
]
],
[
[
463,
64,
168
],
[
168,
23,
985
]
],
[
[
463,
63,
112
],
[
112,
23,
985
]
],
[
[
463,
62,
608
],
[
608,
23,... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} ... | Rifampicin may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may c... |
DB00372 | DB00387 | 999 | 1,386 | [
"DDInter1793",
"DDInter1528"
] | Thiethylperazine | Procyclidine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Moderate | 1 | [
[
[
999,
24,
1386
]
],
[
[
999,
24,
1105
],
[
1105,
1,
1386
]
],
[
[
999,
24,
1376
],
[
1376,
63,
1386
]
],
[
[
999,
63,
352
],
[
352,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procyclidine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenid... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Procyclidine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause... |
DB01259 | DB15982 | 392 | 1,339 | [
"DDInter1024",
"DDInter193"
] | Lapatinib | Berotralstat | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Major | 2 | [
[
[
392,
25,
1339
]
],
[
[
392,
63,
1101
],
[
1101,
23,
1339
]
],
[
[
392,
24,
283
],
[
283,
23,
1339
]
],
[
[
392,
24,
761
],
[
761,
... | [
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratin... |
DB00242 | DB01229 | 1,064 | 973 | [
"DDInter392",
"DDInter1378"
] | Cladribine | Paclitaxel (protein-bound) | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Major | 2 | [
[
[
1064,
25,
973
]
],
[
[
1064,
25,
310
],
[
310,
63,
973
]
],
[
[
1064,
6,
17404
],
[
17404,
45,
973
]
],
[
[
1064,
18,
7824
],
[
7824,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u}... | Cladribine may lead to a major life threatening interaction when taken with Paclitaxel
Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Cladribine (Compound) binds ABCG2 (Gen... |
DB00916 | DB01224 | 112 | 623 | [
"DDInter1202",
"DDInter1553"
] | Metronidazole | Quetiapine | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Minor | 0 | [
[
[
112,
23,
623
]
],
[
[
112,
62,
827
],
[
827,
1,
623
]
],
[
[
112,
6,
8374
],
[
8374,
45,
623
]
],
[
[
112,
21,
29039
],
[
29039,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quetiapine"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trazodone"
],
[
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Trazodone and Trazodone (Compound) resembles Quetiapine (Compound)
Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Quetiapine (Compound)
Metronidazole (Compound) causes Cystitis noninfective (Side Effe... |
DB01268 | DB13139 | 1,151 | 1,032 | [
"DDInter1731",
"DDInter1063"
] | Sunitinib | Levosalbutamol | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1151,
24,
1032
]
],
[
[
1151,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
1151,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1151,
24,
124
],
[
124... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Sunitinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib ... |
DB00694 | DB11979 | 51 | 1,320 | [
"DDInter485",
"DDInter625"
] | Daunorubicin | Elagolix | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
51,
24,
1320
]
],
[
[
51,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
51,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
51,
63,
79
],
[
79,
24... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Os... |
DB06643 | DB09036 | 1,136 | 812 | [
"DDInter500",
"DDInter1668"
] | Denosumab | Siltuximab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
1136,
24,
812
]
],
[
[
1136,
63,
147
],
[
147,
24,
812
]
],
[
[
1136,
24,
1456
],
[
1456,
63,
812
]
],
[
[
1136,
24,
713
],
[
713,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Veneto... |
DB00059 | DB00549 | 1,560 | 522 | [
"DDInter1404",
"DDInter1955"
] | Pegaspargase | Zafirlukast | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
1560,
24,
522
]
],
[
[
1560,
24,
165
],
[
165,
40,
522
]
],
[
[
1560,
24,
1347
],
[
1347,
62,
522
]
],
[
[
1560,
24,
786
],
[
786,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Zafirlukast (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can... |
DB00283 | DB00981 | 701 | 1,528 | [
"DDInter395",
"DDInter1462"
] | Clemastine | Physostigmine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
701,
24,
1528
]
],
[
[
701,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
701,
24,
508
],
[
508,
24,
1528
]
],
[
[
701,
35,
1511
],
[
1511,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is... | Clemastine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Phys... |
DB00530 | DB08875 | 1,195 | 1,618 | [
"DDInter667",
"DDInter262"
] | Erlotinib | Cabozantinib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1195,
24,
1618
]
],
[
[
1195,
24,
384
],
[
384,
63,
1618
]
],
[
[
1195,
23,
307
],
[
307,
24,
1618
]
],
[
[
1195,
24,
1249
],
[
1249,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil... |
DB01075 | DB01202 | 1,376 | 1,435 | [
"DDInter569",
"DDInter1046"
] | Diphenhydramine | Levetiracetam | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
1376,
24,
1435
]
],
[
[
1376,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
1376,
63,
701
],
[
701,
24,
1435
]
],
[
[
1376,
35,
272
],
[
272... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
... | Diphenhydramine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate disea... |
DB00434 | DB00794 | 13 | 759 | [
"DDInter459",
"DDInter1521"
] | Cyproheptadine | Primidone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
13,
24,
759
]
],
[
[
13,
24,
697
],
[
697,
40,
759
]
],
[
[
13,
63,
362
],
[
362,
1,
759
]
],
[
[
13,
24,
157
],
[
157,
1,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (... |
DB00651 | DB00728 | 746 | 1,610 | [
"DDInter613",
"DDInter1612"
] | Dyphylline | Rocuronium | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Moderate | 1 | [
[
[
746,
24,
1610
]
],
[
[
746,
24,
728
],
[
728,
40,
1610
]
],
[
[
746,
21,
29118
],
[
29118,
60,
1610
]
],
[
[
746,
40,
1031
],
[
1031,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
[
... | Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Dyphylline (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Rocuronium (Compound)
Dyphylline (Compound) resembles Theophyl... |
DB00598 | DB09122 | 1,523 | 1,613 | [
"DDInter1013",
"DDInter1409"
] | Labetalol | Peginterferon beta-1a | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1523,
24,
1613
]
],
[
[
1523,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
1523,
25,
1011
],
[
1011,
24,
1613
]
],
[
[
1523,
63,
1560
],
[
15... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Labetalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolim... |
DB00524 | DB01069 | 811 | 401 | [
"DDInter1199",
"DDInter1533"
] | Metolazone | Promethazine | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
811,
24,
401
]
],
[
[
811,
24,
1264
],
[
1264,
63,
401
]
],
[
[
811,
24,
104
],
[
104,
24,
401
]
],
[
[
811,
21,
28709
],
[
28709,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00553 | DB00697 | 92 | 876 | [
"DDInter1177",
"DDInter1821"
] | Methoxsalen | Tizanidine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Major | 2 | [
[
[
92,
25,
876
]
],
[
[
92,
6,
7950
],
[
7950,
45,
876
]
],
[
[
92,
18,
8386
],
[
8386,
57,
876
]
],
[
[
92,
21,
28882
],
[
28882,
... | [
[
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Methoxsalen",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizan... | Methoxsalen (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Methoxsalen (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Tizanidine (Compound)
Methoxsalen (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect... |
DB09034 | DB14568 | 1,313 | 982 | [
"DDInter1733",
"DDInter1000"
] | Suvorexant | Ivosidenib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1313,
24,
982
]
],
[
[
1313,
63,
1101
],
[
1101,
23,
982
]
],
[
[
1313,
63,
770
],
[
770,
24,
982
]
],
[
[
1313,
23,
1135
],
[
1135,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalido... |
DB00850 | DB09278 | 1,630 | 852 | [
"DDInter1432",
"DDInter24"
] | Perphenazine | Activated charcoal | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
1630,
24,
852
]
],
[
[
1630,
63,
127
],
[
127,
24,
852
]
],
[
[
1630,
24,
1411
],
[
1411,
24,
852
]
],
[
[
1630,
1,
1178
],
[
1178,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
]... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide a... |
DB00771 | DB00909 | 262 | 306 | [
"DDInter397",
"DDInter1971"
] | Clidinium | Zonisamide | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
262,
25,
306
]
],
[
[
262,
24,
407
],
[
407,
63,
306
]
],
[
[
262,
63,
475
],
[
475,
24,
306
]
],
[
[
262,
24,
537
],
[
537,
64,... | [
[
[
"Clidinium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a... |
DB00619 | DB12147 | 1,419 | 241 | [
"DDInter909",
"DDInter661"
] | Imatinib | Erdafitinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
1419,
24,
241
]
],
[
[
1419,
25,
1456
],
[
1456,
24,
241
]
],
[
[
1419,
24,
384
],
[
384,
24,
241
]
],
[
[
1419,
25,
982
],
[
982,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
... | Imatinib may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a m... |
DB00365 | DB00653 | 839 | 544 | [
"DDInter842",
"DDInter1120"
] | Grepafloxacin | Magnesium sulfate | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Moderate | 1 | [
[
[
839,
24,
544
]
],
[
[
839,
24,
1473
],
[
1473,
63,
544
]
],
[
[
839,
25,
175
],
[
175,
24,
544
]
],
[
[
839,
25,
167
],
[
167,
6... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium sulfate"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluc... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate
Grepafloxacin may lead to a major life threatening interaction when taken with Triam... |
DB00059 | DB08827 | 1,560 | 990 | [
"DDInter1404",
"DDInter1085"
] | Pegaspargase | Lomitapide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
1560,
25,
990
]
],
[
[
1560,
24,
1409
],
[
1409,
24,
990
]
],
[
[
1560,
24,
1421
],
[
1421,
63,
990
]
],
[
[
1560,
24,
1387
],
[
1387,... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrix... |
DB09133 | DB12615 | 1,527 | 1,381 | [
"DDInter965",
"DDInter1482"
] | Iothalamic acid | Plazomicin | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Major | 2 | [
[
[
1527,
25,
1381
]
],
[
[
1527,
64,
416
],
[
416,
24,
1381
]
],
[
[
1527,
64,
1441
],
[
1441,
25,
1381
]
],
[
[
1527,
64,
416
],
[
416,
... | [
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
]
],
[
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
... | Iothalamic acid may lead to a major life threatening interaction when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Iothalamic acid may lead to a major life threatening interaction when taken with Bacitracin and Bacitracin may lead to a maj... |
DB06636 | DB09075 | 1,623 | 498 | [
"DDInter980",
"DDInter621"
] | Isavuconazonium | Edoxaban | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
1623,
24,
498
]
],
[
[
1623,
62,
222
],
[
222,
24,
498
]
],
[
[
1623,
24,
1017
],
[
1017,
63,
498
]
],
[
[
1623,
25,
1476
],
[
1476,
... | [
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Isavuconazonium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib an... |
DB00448 | DB11071 | 1,215 | 1,004 | [
"DDInter1022",
"DDInter1449"
] | Lansoprazole | Phenyl salicylate | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Minor | 0 | [
[
[
1215,
23,
1004
]
],
[
[
1215,
40,
837
],
[
837,
23,
1004
]
],
[
[
1215,
24,
416
],
[
416,
24,
1004
]
],
[
[
1215,
23,
256
],
[
256,
... | [
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may ca... | Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction... |
DB00831 | DB01087 | 1,178 | 1,520 | [
"DDInter1866",
"DDInter1520"
] | Trifluoperazine | Primaquine | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
1178,
24,
1520
]
],
[
[
1178,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
1178,
6,
7950
],
[
7950,
45,
1520
]
],
[
[
1178,
21,
28722
],
[
28... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[... | Trifluoperazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Trifluoperazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Primaquine (Compound)
Trifluoperazine (Compo... |
DB06228 | DB14975 | 792 | 988 | [
"DDInter1609",
"DDInter1949"
] | Rivaroxaban | Voxelotor | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
792,
24,
988
]
],
[
[
792,
63,
222
],
[
222,
23,
988
]
],
[
[
792,
24,
466
],
[
466,
23,
988
]
],
[
[
792,
64,
126
],
[
126,
24,... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Dar... |
DB05015 | DB12130 | 1,077 | 1,017 | [
"DDInter174",
"DDInter1094"
] | Belinostat | Lorlatinib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1077,
24,
1017
]
],
[
[
1077,
25,
976
],
[
976,
24,
1017
]
],
[
[
1077,
63,
139
],
[
139,
24,
1017
]
],
[
[
1077,
24,
738
],
[
738,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitin... | Belinostat may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may caus... |
DB01261 | DB01284 | 170 | 1,042 | [
"DDInter1679",
"DDInter1782"
] | Sitagliptin | Tetracosactide | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
170,
24,
1042
]
],
[
[
170,
63,
455
],
[
455,
23,
1042
]
],
[
[
170,
24,
659
],
[
659,
62,
1042
]
],
[
[
170,
63,
811
],
[
811,
... | [
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vi... |
DB00612 | DB00986 | 1,121 | 1,192 | [
"DDInter216",
"DDInter834"
] | Bisoprolol | Glycopyrronium | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
1121,
24,
1192
]
],
[
[
1121,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
1121,
24,
262
],
[
262,
24,
1192
]
],
[
[
1121,
21,
29231
],
[
292... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and C... |
DB04861 | DB06703 | 1,592 | 619 | [
"DDInter1271",
"DDInter793"
] | Nebivolol | Gadobutrol | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to ot... | Moderate | 1 | [
[
[
1592,
24,
619
]
],
[
[
1592,
21,
28810
],
[
28810,
60,
619
]
],
[
[
1592,
24,
1013
],
[
1013,
63,
619
]
],
[
[
1592,
21,
28810
],
[
28... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobutrol"
]
],
[
[
"Nebivolol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u}... | Nebivolol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Gadobutrol (Compound)
Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate ... |
DB06206 | DB09389 | 1,268 | 517 | [
"DDInter1719",
"DDInter1315"
] | Sugammadex | Norgestrel | Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general ane... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Major | 2 | [
[
[
1268,
25,
517
]
],
[
[
1268,
63,
279
],
[
279,
62,
1647
],
[
1647,
24,
517
]
],
[
[
1268,
63,
11
],
[
11,
24,
723
],
[
723,
24,
... | [
[
[
"Sugammadex",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Sugammadex",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindio... | Sugammadex may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Sugammadex... |
DB00850 | DB01124 | 1,630 | 1,411 | [
"DDInter1432",
"DDInter1828"
] | Perphenazine | Tolbutamide | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1630,
24,
1411
]
],
[
[
1630,
24,
959
],
[
959,
40,
1411
]
],
[
[
1630,
63,
245
],
[
245,
40,
1411
]
],
[
[
1630,
6,
10215
],
[
10215,... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Comp... |
DB00202 | DB01172 | 190 | 416 | [
"DDInter1716",
"DDInter1004"
] | Succinylcholine | Kanamycin | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Major | 2 | [
[
[
190,
25,
416
]
],
[
[
190,
21,
28680
],
[
28680,
60,
416
]
],
[
[
190,
24,
608
],
[
608,
23,
416
]
],
[
[
190,
24,
91
],
[
91,
2... | [
[
[
"Succinylcholine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compo... | Succinylcholine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Kanamycin (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Kanamycin
Su... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.